His research focuses on policies related to drug safety and effectiveness evaluation in the context of regulation and evidence synthesis. He is an advocate for greater public access to clinical trial data, and maintains a strong interest in journalism as a vehicle for encouraging better practice and improving the research enterprise. Since 2009, he has worked with a team that sifted through FDA approval packages and formerly confidential clinical study reports of the anti-influenza drugs oseltamivir and zanamivir. He completed a post-doctoral fellowship in comparative effectiveness research at Johns Hopkins University and received his doctorate in history, anthropology, and science, technology and society from the Massachusetts Institute of Technology.